ECOR electroCore

electroCore Presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference

electroCore Presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference

ROCKAWAY, NJ, Sept. 30, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference has been rescheduled to today, September 30, 2021 at 12:40 PM eastern time. 

Details for the company’s presentation are as follows:

Cantor Fitzgerald Virtual Global Healthcare Conference:

Date: Thursday, September 30, 2021

Rescheduled Time: 12:40 pm EDT

Investors can register for the conference

Following the conference a webcast replay of the presentation will be available on the Investor section of the company’s website, .

About electroCore, Inc.

electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology. The company's current indications are the preventive treatment of cluster headache and migraine and the acute treatment of migraine and episodic cluster headache.

For more information, visit .



Investors:
Rich Cockrell
CG Capital
404-736-3838
 tal

or

Media Contact:
Jackie Dorsky
electroCore
908-313-6331
EN
30/09/2021

Underlying

ECORelectroCore

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on electroCore

 PRESS RELEASE
Free
ECOR ELECTROCORE

electroCore Announces Third Quarter 2025 Financial Results

electroCore Announces Third Quarter 2025 Financial Results Net sales of $8.7 million increased 33% vs. Q3 2024; YTD net sales of $22.8 million increased 26% vs. first nine months of 2024 Cash, cash equivalents, restricted cash, and marketable securities (“Total Cash”) of $13.2 million as of September 30, 2025  Company to host a conference call and webcast today, November 5, 2025, at 4:30 p.m. EDT ROCKAWAY, N.J., Nov. 05, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company, today announced financial results for t...

November 5, 2025 1 EN
 PRESS RELEASE
Free
ECOR ELECTROCORE

electroCore to Announce Third Quarter September 30, 2025 Financial Res...

electroCore to Announce Third Quarter September 30, 2025 Financial Results on Wednesday, November 5, 2025 ROCKAWAY, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial results for the third quarter ended September 30, 2025, after the close of the market on Wednesday, November 5, 2025. Management will host a webinar at 4:30 PM EST to review the financial results and answer questions. Investors can access the webinar using the details below: Wednesday, Novemb...

October 23, 2025 1 EN
 PRESS RELEASE
Free
ECOR ELECTROCORE

electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(...

electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4) ROCKAWAY, N.J., Oct. 03, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Jennifer Hayes will be joining electroCore, effective October 6, 2025, as the Company’s Vice President, Human Resources and Employee Success. The Compensation Committee of electroCore’s Board of Directors granted 10,000 restricted stock units (“RSUs”) to Ms. Hayes in connection with the commencement of her employment. The RSUs were...

October 3, 2025 1 EN
 PRESS RELEASE
Free
ECOR ELECTROCORE

gammaCore® Non-Invasive Vagus Nerve Stimulation (nVNS) as an Adjunctiv...

gammaCore® Non-Invasive Vagus Nerve Stimulation (nVNS) as an Adjunctive Treatment Associated with Improvements in Persistent Post-Concussion Symptoms ROCKAWAY, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the publication of a peer-reviewed study in Frontiers in Neurology demonstrating the effectiveness of gammaCore® non-invasive vagus nerve stimulation (nVNS) in reducing persistent symptoms associated with mild traumatic brain injury (mTBI). “The CDC reports approximately 2.5 mil...

September 30, 2025 1 EN
 PRESS RELEASE
Free
ECOR ELECTROCORE

electroCore Announces Reimbursement Approval for gammaCore™ by RIZIV/I...

electroCore Announces Reimbursement Approval for gammaCore™ by RIZIV/INAMI in Belgium ROCKAWAY, N.J., Sept. 29, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that gammaCore™ Sapphire (nVNS) has been included in a long-term reimbursement policy launched by the National Institute for Health and Disability Insurance (RIZIV / INAMI) in Belgium. Effective October 1, 2025, the policy provides coverage for gammaCore Sapphire to treat patients with cluster headaches. This coverage is based on strong clin...

September 29, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch